Promise Bio has launched the Frontier Epiproteomic Innovation Grant, providing selected biotech companies with access to epiproteomic profiling and expert analysis to support translational research.

The program offers comprehensive analysis of up to 200 samples, including detection of 64 post-translational modifications (PTMs), proteoform-specific analysis, quality control, advanced bioinformatics, and scientific interpretation. All analysis uses existing or newly generated mass-spectrometry data, with no additional wet-lab experimentation required.

Dr. Ronel Veksler, co-founder and CEO of Promise Bio, said: “The Epiproteomic Innovation Grant is our commitment to providing biotech companies with data that can inform critical R&D decisions and support translational drug development.”

The grant is open to clinical-stage biotech companies working in immunology, neurology, or cardio-renal-metabolic diseases. Priority will be given to proposals addressing decision-relevant questions, including mechanisms of action, biomarker discovery, patient stratification, and drug-response prediction.

Promise Bio’s platform enables broad profiling of PTMs and proteoforms without custom chemical enrichment or additional laboratory procedures. The technology was developed at the Weizmann Institute of Science and reported in Nature Biotechnology in 2023, allowing researchers to uncover disease mechanisms, inform therapy development, and identify potential drug targets.

Applications are open until April 15, 2026. For more information, visit https://frontier.promise.bio/ or email frontier@promise.bio.